Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guishen Yijing Granules in Diminished Ovarian Reserve
NCT07841548Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, randomised, double-blind trial of Guishen Yijing Granules in Diminished Ovarian Reserve (DOR) (2 arms). Primary endpoint: Anti-Müllerian Hormone. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Guishen Yijing Granules
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT07841548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841548.